Midkine (MK) is a heparin-binding growth factor and its expression is conserved across species and is developmentally regulated. [1] [2] [3] It promotes neurite outgrowth and has a mitogenic activity towards fibroblasts and neuroectoderm cells. 4, 5) The biological function of MK during tumorigenesis is not clearly understood, though MK expression is elevated in various types of human cancer such as Wilms' tumor, 6) breast cancer, 7) and neuroblastoma. 8) Recent studies have shown that MK plays a possible role in enhancing angiogenesis 9) and that overexpression of the MK gene is a poor prognostic factor for patients with bladder carcinoma. 10) In normal adult tissues, MK is expressed solely in the kidney, lung and small intestine.
6) The limited expression in normal tissues implies a possible use of the promoter, which preferentially functions in tumor cells, for therapeutic strategies based on tumor-specific gene expression.
Esophageal cancer remains one of the most intractable tumors due to the higher incidence in aged patients and its rapid infiltration into neighboring tissues despite multimodal approaches. 11) Novel procedures, therefore, should be introduced to improve the prognosis, and gene therapy is a possible therapeutic approach. Increased MK expression in human gastrointestinal tumors was reported, 12) but the expression in esophageal cancer has not been extensively studied. In this study, we examined the expression of the MK gene in human esophageal cancer and found that it was detectable solely in the tumors. We then tested whether the 5′-upstream region of the MK gene could be used as a promoter to generate transcriptional activation in esophageal tumors. For that purpose, the expressions of a reporter gene and the herpes simplex virus-thymidine kinase (HSV-TK) gene, a suicide gene frequently used for gene therapy, 13) were investigated in human esophageal cancer cell lines, using the upstream region of the MK gene. cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Immunohistochemical analysis Human specimens were surgically obtained from 14 Japanese esophageal cancer patients (summarized in Table I ). The samples were fixed with 4% paraformaldehyde/phosphate-buffered saline at 4°C. The sections of 4-5-µm thickness were incubated with 10% skim milk for 20 min, and then with affinitypurified rabbit anti-MK antibody for 60 min. The sections were sequentially reacted with 0.3% H 2 O 2 /methanol, biotinylated anti-rabbit IgG, avidin-horseradish peroxidase complex (Vector Laboratories, Burlingame, CA) and 3,3-diaminobenzidine; they ware washed with phosphate-buffered saline after each reaction. The sections were counterstained with hematoxylin. Northern blot analysis Poly A + mRNA was extracted using an mRNA purification kit (Amersham Pharmacia Biotech, Buckinghamshire, UK). One microgram of mRNA was subjected to electrophoresis in a denaturing formaldehyde-agarose gel and transferred to a nylon filter. The human MK or human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA 14) was 15) was inserted into pCAT-basic vector (Promega, Madison, WI). Two plasmids, CAT gene driven by the SV40 early promoter and CAT gene without promoters, were from Promega. Esophageal cancer cells were transfected with the respective plasmid DNAs containing the CAT gene (10 µg) and 1 µg of DNA which could constitutively express the β-galactosidase gene (pCH110, Amersham Pharmacia Biotech) using Lipofectin reagent (Life Technologies, Gaithersburg, MD). Two days later, cell extracts were prepared by sonication. To normalize the transfection efficiency, the amounts of cell extracts used for CAT assay were adjusted according to the β-galactosidase activity. 16) CAT activity was measured by the incubation of each extract with 50 µCi of [ 18) next to a 2.3 kb MK genomic DNA fragment (see Fig. 4 ) and used in CAT assay. Esophageal and melanoma cells were transfected with the vector DNA bearing the MK+HSV-TK gene using Lipofectin reagent and were cultured in G418 (Life Technologies)-containing medium to obtain stably transfected cells. The G418-resistant or wild-type cells, placed in 96-well plates at the density of 5×10 2 cells/well, were cultured in the absence or presence of various concentrations of GCV (0.1-100 µg/ml) for 7 days. The viable cell number in each well was measured with a cell counting kit (Dojindo Laboratories, Kumamoto). The amounts of formazan produced were determined from the absorbance at 450 nm.
RESULTS

Immunohistochemical analysis
We examined the expression of MK protein in human specimens of esophageal tumors. Eight out of 14 specimens were positively stained with anti-MK antibody, while none of the surrounding normal esophageal tissues in MK-positive specimens reacted with the antibody (Fig. 1) . The tumor cells were cytoplasmically stained with the antibody. We noticed that all the specimens of well differentiated type were stained with the antibody. However, no other correlations of MK expression with clinicopathological features of the patients examined were evident (Table I) . Expression of the MK gene in human esophageal cell lines In order to establish an experimental system using cell lines, we examined the expression of the MK gene in 7 human esophageal cancer cell lines by northern blot analysis. All the lines tested expressed the transcripts but the amounts of the transcript varied among the lines ( 2). In contrast, a human melanoma line, A875, was negative for midkine expression, and a human fibroblast line, HFF, expressed the MK gene but the level of the expression was markedly lower than that of esophageal lines tested (Fig. 2) .
Promoter activity in human esophageal tumor cells
To investigate whether the 5′-upstream region of MK genomic DNA fragment can be used as a transcriptional promoter in human esophageal tumors, we tested CAT activity in 7 esophageal cancer cell lines transfected with the CAT gene-containing plasmid. All the lines tested could transcribe the reporter gene under the control of 2.3 kb MK genomic region (Fig. 3) . However, the transcriptional activites varied among the lines and were not related with the amounts of the MK transcript (Fig. 2) . Relative CAT activity powered by the putative MK promoter was less than that of the SV40 promoter in 5 lines. The activity of the MK promoter judged in terms of acetylation rate was 6.0-30% of that of the SV40 promoter. In contrast, 2 lines (TE13 and T.Tn) showed CAT activity comparable to that of the SV40 promoter (85-160%).
In vitro sensitivity We then examined the antitumor effect in terms of the expression of the HSV-TK gene controlled by the putative MK promoter. To avoid the effect of the promoter present in the 5′-long terminal repeat of the retrovirus vector, the putative MK promoter-driven HSK-TK gene was inserted in an antisense orientation opposite to that of the retroviral promoter (Fig. 4A) . 19, 20) The plasmid was then transfected into TE13, TE1 and A875 cells, and the pooled G418-resistant cells were tested for their sensitivity to GCV. The transfected TE13 and TE1 cells showed increased sensitivity compared with the respective parent cells (Fig. 4 , B and C), whereas the sensitivity of MK-negative A875 cells remained the same as that of untransfectecd cells (Fig. 4D) . In each experiment, the cells transfected with control DNA bearing the HSV-TK gene without the putative MK promoter showed Table I Plabeled MK cDNA and the same filter was rehybridized with 32 P-labeled GAPDH cDNA. The approximate sizes of the MK and GAPDH transcripts are 0.9 kb and 1.8 kb, respectively. the same sensitivity as found in wild-type cells (data not shown).
DISCUSSION
In this study we have shown that human esophageal tumors express MK. At the transcriptional level all the human esophageal cancer cell lines tested expressed a large amount of MK mRNA compared with a melanoma and a fibroblast line (Fig. 2) . In immunohistochemical staining, more than half of the human specimens from esophageal tumors reacted with anti-MK antibody, in contrast to the surrounding normal esophageal tissues (Fig.  1) . Aridome et al. analyzed the MK expression in 2 human esophageal tumors and detected the transcript in tumors, but not in non-cancerous regions. 12) We did not find any correlation between the MK expression in esophageal tumors and the clinical outcome of the patients (data not shown). However, high MK expression in tumors was shown to be a poor prognostic marker in neuroblastoma 8) and bladder cancer patients. 10) Further investigations are necessary to assess the clinical value of the MK expression in esophageal cancer.
Recently we have shown that forced expression of the MK gene could transform NIH3T3 cells 21) and that MK expression was elevated in the early stage of carcinogenesis in human colorectal cancer. 22) However, the biological significance of the MK expression in tumor cells remains unclear. Nevertheless, the 5′-flanking region of the MK gene could be useful for tumor-specific expression. Usefulness of the expression of the HSV-TK gene in tumors, followed by GCV administration, has been investigated in various animal models 23, 24) and its clinical application is being tested. 25) We found that the 2.3 kb-upstream region of the MK gene contained a promoter activity which could initiate transcription of the fused CAT gene in esophageal cancer cell lines (Fig. 3 ). Among the lines tested, two (TE13, T.Tn) showed strong transcriptional activity which was comparable to that of the SV40 promoter. A cytotoxic effect caused by GCV was seen in 2 cell lines, TE13 and TE1, when they were transfected with the HSV-TK gene driven by the MK promoter (Fig. 4, B and C) . However, their CAT activity generated by the putative MK promoter was not correlated with their sensitivity (Fig. 3) . A low level of promoter activity may be enough to transcribe the HSV-TK gene and to convert GCV to phosphorylated GCV. The specificity of MK-based transcription was confirmed by the finding that MK-negative A875 cells did not show increased sensitivity to GCV after transfection with MK-driven HSV-TK gene (Fig. 4D) . We observed discordant results between the amount of transcript and the promoter activity in esophageal cancer cell lines (Figs. 2 and 3 ). Since the CAT assay solely detects cis-acting elements, the steady-state level of the transcript may be influenced by other elements. Analysis of the promoter region of the MK gene revealed that it contained a retinoic acid-responsive element. 26) Upregulation of the transcriptional activity by retinoic acid can be observed in tumor cells. The expression of the WT1 gene, a tumor suppressor gene identified in Wilms' tumor, was shown to suppress the MK expression and two possible WT1 binding sites were identified in the promoter region. 27) This is an intriguing clue to the mechanism of elevated expression of the MK gene in Wilms' tumor. 6) However, the expression of the WT1 gene is restricted, 28) and expression in the esophagus has not been reported. Recently, loss of WT1 expression in colon carcinoma and in breast cancer, whose MK expression was elevated, 7, 12) were demonstrated. 29, 30) Therefore, the biological relevance of the expression of WT1 and that of MK requires further study.
Esophageal tumors occur frequently in aged patients, in whom intensive therapeutic maneuvers may be inappropriate. Several strategies such as combinations of conven- tional therapies have had limited success in improving the prognosis and the quality of life of patients. The present study suggests a possible gene therapy using a suicide gene/prodrug system. Tumor-specific expression of suicide gene(s) followed by the administration of prodrug(s) can destroy tumor cells without causing serious damage to normal tissues. Obstruction of the esophagus, a complication often found in patients, might be treatable in part by endoscopic injection of vectors bearing the MK promoterdriven suicide gene(s) and non-toxic prodrug administration. The treatment is less invasive than surgery, and should alleviate the patient's discomfort. Gene therapy with tumor specificity achieved by the usage of the MK promoter, whose activity may be enhanced by retinoic acid, seems to be worth testing in patients with esophageal cancer.
